- Home
- DCTH vs GNFT Comparison
DCTH vs GNFT Comparison
Compare DCTH & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- GNFT
- Stock Information
- Founded
- DCTH 1988
- GNFT 1999
- Country
- DCTH United States
- GNFT France
- Employees
- DCTH N/A
- GNFT N/A
- Industry
- DCTH Medical/Dental Instruments
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DCTH Health Care
- GNFT Health Care
- Exchange
- DCTH Nasdaq
- GNFT Nasdaq
- Market Cap
- DCTH 379.5M
- GNFT 296.4M
- IPO Year
- DCTH N/A
- GNFT 2019
- Fundamental
- Price
- DCTH $12.27
- GNFT $3.83
- Analyst Decision
- DCTH Strong Buy
- GNFT Strong Buy
- Analyst Count
- DCTH 4
- GNFT 1
- Target Price
- DCTH $21.50
- GNFT $13.00
- AVG Volume (30 Days)
- DCTH 389.6K
- GNFT 7.6K
- Earning Date
- DCTH 11-08-2024
- GNFT 09-19-2024
- Dividend Yield
- DCTH N/A
- GNFT N/A
- EPS Growth
- DCTH N/A
- GNFT N/A
- EPS
- DCTH N/A
- GNFT 0.47
- Revenue
- DCTH $22,644,000.00
- GNFT $86,225,222.00
- Revenue This Year
- DCTH $1,605.13
- GNFT $155.44
- Revenue Next Year
- DCTH $111.67
- GNFT N/A
- P/E Ratio
- DCTH N/A
- GNFT $8.03
- Revenue Growth
- DCTH 945.91
- GNFT 175.45
- 52 Week Low
- DCTH $3.10
- GNFT $3.31
- 52 Week High
- DCTH $12.88
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- DCTH 63.93
- GNFT 26.67
- Support Level
- DCTH $11.36
- GNFT $3.89
- Resistance Level
- DCTH $12.10
- GNFT $4.06
- Average True Range (ATR)
- DCTH 0.69
- GNFT 0.12
- MACD
- DCTH 0.10
- GNFT 0.00
- Stochastic Oscillator
- DCTH 84.97
- GNFT 8.82
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.